This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-13 (Canceled).

14. (Withdrawn) ~~Method~~A method for rapid angiogenensis targeting ~~wherein an antibody with specific affinity for a characteristic epitope of the ED-B domain of fibronectin, the antibody having improved affinity to said ED-B domain, is used~~ comprising administering an antibody conjugate of claim 20.

15. (Withdrawn) ~~Method~~The method according to claim 14 for immunoscintigraphic detection of angiogenesis.

16. (Withdrawn) ~~Method~~The method according to claim 15 for detecting diseases characterized by vascular proliferation ~~such as diabetic retinopathy, age-relatd macular degeneration or tumours~~.

17. (Withdrawn) ~~Method~~The method according to claim 14, wherein the antibody localizes the ~~respective~~ target tissue three to four hours~~, most preferably 3 hours~~ after its injection.

Claim 18 (Canceled).

19. (Withdrawn) ~~Method~~A method for ~~diagnosis and~~ therapy of a tumours ~~and~~ or a diseases characterized by vascular proliferation ~~wherein an antibody with specific affinity for a characteristic epitope of the ED-B domain of fibronectin, said antibody having improved affinity to said ED-B domain, is used~~ comprising administering an antibody conjugate of claim 20.

20. (Currently Amended) ~~A~~ The conjugate comprising an antibody with ~~a specific, high~~ an affinity (Kd) for the ED-B domain of fibronectin of less than about 54pM, and a molecule which induces blood coagulation and blood vessel occlusion.

21. (Currently Amended) ~~A~~ The conjugate according to claim 20 wherein the molecule which induces blood coagulation and blood vessel occlusion is a photoactive molecule.

22. (Currently Amended) ~~A~~ The conjugate according to claim 21 wherein the photoactive molecule is a photosensitizer.

23. (Currently Amended) ~~A~~ The conjugate according to claim 22 wherein the photosensitizer absorbs at a wavelength above 600 nm.

24. (Currently Amended) ~~A~~ The conjugate according to claim 22 wherein the photosensitizer is a derivative of tin (IV) chlorine e6.

25. (Withdrawn) ~~Method a~~ The method for the treatment of an angiogenesis-related ~~pathologies wherein~~ a pathology comprising injecting a conjugate according to claim 20 ~~is injected~~.

26. (Withdrawn) ~~Method a~~ The method for the treatment of an angiogenesis-related ~~pathologies wherein~~ a pathology comprising injecting a conjugate according to claim 22 ~~is injected~~, followed by irradiation.

27. (Withdrawn) ~~Method a~~ The method according to claim 26 wherein the angiogenesis-related pathology treated is caused by ~~a~~ or associated with ocular angiogenesis.

28. (Currently Amended) ~~A~~ The conjugate according to claim 20, wherein said affinity is ~~in the subnamomolar range~~ 27 to 54pM.

29. (Currently Amended) ~~A~~ The conjugate according to claim 28 wherein the molecule which induces blood coagulation and blood vessel occlusion is a photoactive molecule.

30. (Currently Amended) ~~A~~ The conjugate according to claim 29 wherein the photoactive molecule is a photosensitizer.

31. (Currently Amended) ~~A~~ The conjugate according to claim 30 wherein the photosensitizer absorbs at a wavelength above 600 nm.

32. (Currently Amended) ~~A~~ The conjugate according to claim 30 wherein the photosensitizer is a derivative of tin (IV) chlorine e6.

33. (Currently Amended) ~~A~~ The conjugate according to claim 20, wherein the antibody is an scFv antibody.

34. (Currently Amended) ~~A~~ The conjugate according to claim 33, wherein the antibody is a recombinant antibody.

35. (Currently Amended) ~~A conjugate~~The conjugate according to claim 33, ~~wherein the antibody comprises a limited number of mutations in its CDR residues~~ further comprising at least one mutation in one or more residues of its CDR regions, which increases the affinity of the antibody for the ED-B domain.

36. (Currently Amended) ~~A conjugate according to~~ The conjugate of claim ~~35~~ 38 further comprising at least one mutation in one or more residues of its CDR regions, wherein the ~~mutated residues~~ affinity of the antibody for the ED-B domain is increased, and wherein said mutation(s) are in at least one residue corresponding to residues 31-33, 50, 52 and/or 54 of ~~its~~ the VH domain of SEQ ID NO: 30 and/or residues 32 and/or 50 of ~~its~~ the VL domain of SEQ ID NO: 32.

37. (Currently Amended) ~~A~~ The conjugate according to claim 28, wherein the antibody binds to the ED-B domain of fibronectin with a K_d of about 54 pM.

38. (Currently Amended) ~~A~~ The conjugate according to claim 28 with the following amino acid sequence

VH domain (SEQ ID NO: 19)

EVQLLESGGG LVQPGGSLRL SCAASGFTFS
SFSMSWVRQA PGKGLEWVSS ISGSSGTTYY
ADSVKGRFTI SRDNSKNTLY LQMNSLRAED
TAVYYCAKPF PYFDYWGQGT LVTVSS

Linker (SEQ ID NO: 20)

GDGSSGGSGGASTG

VL domain (SEQ ID NO: 21)

EIVLTQSPGT LSLSPGERAT LSCRASQSVS
SSYLAWYQQK PGQAPRLLIY YASSRATGIP
DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ
QTGRIPPTFG QGTKVEIK

39. (Currently Amended) ~~A~~ The conjugate according to claim 20, wherein said affinity is about ~~0.05 nM~~ 50-54pM.

40. (New) The conjugate according to claim 20, wherein the fibronectin is human.

41. (New) The conjugate according to claim 20, wherein the antibody comprises the VH domain of SEQ ID 19.

42. (New) The conjugate according to claim 20, wherein the antibody comprises the VL domain of SEQ ID 21.

43. (New) The conjugate according to claim 35, wherein the number of mutations is 1-3.

44. (New) The conjugate according to claim 43, wherein the number of mutations is 2.

45. (New) The conjugate according to claim 44, wherein the number of mutations is 1.

46. (New) The conjugate according to claim 36, wherein the number of mutations is 1-3.

47. (New) The conjugate according to claim 46, wherein the number of mutations is 2.

48. (New) The conjugate according to claim 47, wherein the number of mutations is 1.

49. (New) The method of claim 16 wherein said disease is diabetic retinopathy, age-related macular degeneration or a tumour.

50. (New) The method of claim 17 wherein said antibody localizes in three hours.